GSK’s Antibiotic Gepotidacin Nears Approval Line

There have been no new class of oral antibiotics for uncomplicated urinary tract infections approved for over two decades. With a priority review secured in the US, GSK's triazaacenaphthylene offering could make it to market by March next year.

GSK

More from Scrip

More from Therapy Areas